ANIP
Neutral signalScored 2026-10-21 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
ANI Pharmaceuticals, Inc.
- Nom
- ANI Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - Specialty & Generic
- Bourse
- NASDAQ
- Capitalisation
- $1.7B
- Employés
- 970
- PDG
- Nikhil Lalwani
- Site web
- https://www.anipharmaceuticals.com
- Marché
- AMPHAMRXBHCCOLLEOLSHROW
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 11 800 titres (~843 136,00 $ US)
- Insiders
- Lalwani NikhilThoma Jeanne
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,245,166
Avg sell (VWAP, 90d window) $73.83 vs last close $72.60 (-1.7%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$2,001,692 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-15
- Liquidity
- Liquid $24,435,871/day · 20d vol
- Last synced
-
2026-10-26 21:10:07
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Lalwani Nikhil | Sell · S · 10b5-1 | 5,400 | $71.89 | $388,206 | Form 4 |
| 2026-10-13 | Cook Meredith | Sell · S · 10b5-1 | 500 | $73.59 | $36,795 | Form 4 |
| 2026-09-29 | CAREY STEPHEN P. | Sell · S · 10b5-1 | 2,850 | $73.00 | $208,050 | Form 4 |
| 2026-09-15 | Lalwani Nikhil | Sell · S · 10b5-1 | 5,400 | $71.00 | $383,400 | Form 4 |
| 2026-09-14 | Cook Meredith | Sell · S · 10b5-1 | 500 | $70.79 | $35,395 | Form 4 |
| 2026-09-11 | Thoma Jeanne | Sell · S · 10b5-1 | 1,000 | $71.53 | $71,530 | Form 4 |
| 2026-08-31 | CAREY STEPHEN P. | Sell · S · 10b5-1 | 2,850 | $72.80 | $207,480 | Form 4 |
| 2026-08-25 | Lalwani Nikhil | Sell · S · 10b5-1 | 5,400 | $74.30 | $401,220 | Form 4 |
| 2026-08-13 | Cook Meredith | Sell · S · 10b5-1 | 500 | $75.48 | $37,740 | Form 4 |
| 2026-08-10 | Gutwerg Ori | Sell · S | 3,162 | $77.00 | $243,474 | Form 4 |
| 2026-07-29 | CAREY STEPHEN P. | Sell · S · 10b5-1 | 2,850 | $81.36 | $231,876 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-21 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
ANIP exhibits genuinely strong financial fundamentals — a clear profitability turnaround, robust EBITDA margins, and high liquidity (scores 90/85) — that provide a solid structural floor.
The first sentence of the analysis written for ANIP on 2026-10-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 2.71 · operating margin 9.2%
Suggested stop 70.59, nearest stored support minus 0.5 ATR(2.8% under the last close). Reward/risk to the next stored resistance is 2.76. Research, not advice. Not an order.
Recent news
- 2026-10-19 ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI''s Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug (RLD) Cymbalta®.
- 2026-10-19 ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $388,206.00 in Stock ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) CEO Nikhil Lalwani sold 5,400 shares of the firm''s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $71.89, for a total transaction of $388,206.00. Following the completion of the transaction, the chief executive officer owned 333,689
- 2026-10-13 Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 2026-10-13 These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
- 2026-10-06 Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH) Talphera (NASDAQ: TLPH - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends. Analyst Recommendations This is a summary of current
- 2026-09-30 ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026
- 2026-09-28 Implied Volatility Surging for ANI Pharmaceuticals Stock Options Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
- 2026-09-24 ANI Pharmaceuticals: Cortrophin''s Q4 Test, With Generics Funding The Build ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected to comprise nearly 60% of 2026 revenue. Cortrophin guidance was lowered by ~$30M, but H2 expectations remain intact, with Q4 growth hinging on gout salesforce productivity.
- 2026-09-23 ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI''s Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®.
- 2026-09-14 ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 51.0% | 59.3% | 62.7% | 56.1% | 53.5% | |
| Ebit Margin | 13.1% | -0.8% | 9.6% | -10.9% | -20.4% | |
| Ebitda Margin | 23.5% | 10.3% | 21.9% | 7.9% | 1.4% | |
| Operating Profit Margin | 9.2% | 0.1% | 9.6% | -11.2% | -18.4% | |
| Pretax Profit Margin | 10.8% | -3.6% | 4.1% | -19.8% | -25.9% | |
| Continuous Operations Profit Margin | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% | |
| Net Profit Margin | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% | |
| Bottom Line Profit Margin | 8.0% | -3.3% | 3.5% | -15.7% | -19.8% | |
| Current Ratio | 2.708 | 2.725 | 3.573 | 3.462 | 3.676 | |
| Quick Ratio | 2.194 | 2.018 | 2.809 | 2.403 | 2.743 | |
| Solvency Ratio | 0.189 | 0.058 | 0.176 | 0.028 | 0.011 | |
| Cash Ratio | 1.027 | 0.748 | 1.520 | 0.485 | 1.146 | |
| Price To Earnings Ratio | 22.554 | -53.154 | 58.042 | -13.190 | -13.553 | |
| Price To Earnings Growth Ratio | -0.052 | 0.254 | -0.443 | 1.281 | -0.168 | |
| Forward Price To Earnings Growth Ratio | -0.052 | 0.254 | -0.443 | 1.281 | -0.168 | |
| Price To Earnings Diluted Ratio | 23.777 | -53.154 | 58.660 | -13.190 | -13.553 | |
| Price To Earnings Diluted Growth Ratio | -0.057 | 0.252 | -0.448 | 1.281 | -0.168 | |
| Price To Book Ratio | 2.928 | 2.492 | 2.169 | 1.932 | 1.618 | |
| Price To Sales Ratio | 1.792 | 1.738 | 2.039 | 2.068 | 2.685 | |
| Price To Free Cash Flow Ratio | 10.490 | 22.690 | 9.881 | -13.726 | -28.570 | |
| Price To Operating Cash Flow Ratio | 8.546 | 16.681 | 8.344 | -20.964 | 174.721 | |
| Debt To Assets Ratio | 0.226 | 0.486 | 0.316 | 0.377 | 0.372 | |
| Debt To Equity Ratio | 0.601 | 1.456 | 0.624 | 0.846 | 0.801 | |
| Debt To Capital Ratio | 0.376 | 0.593 | 0.384 | 0.458 | 0.445 | |
| Long Term Debt To Capital Ratio | 0.363 | 0.589 | 0.384 | 0.458 | 0.444 | |
| Financial Leverage Ratio | 2.664 | 2.996 | 1.976 | 2.245 | 2.151 | |
| Working Capital Turnover Ratio | 2.184 | 1.735 | 1.573 | 1.321 | 1.326 | |
| Operating Cash Flow Ratio | 0.666 | 0.331 | 0.818 | -0.314 | 0.038 | |
| Operating Cash Flow Sales Ratio | 0.210 | 0.104 | 0.244 | -0.099 | 0.015 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.815 | 0.735 | 0.844 | 1.527 | -6.116 | |
| Debt Service Coverage Ratio | 5.085 | 2.495 | 3.797 | 1.377 | 1.297 | |
| Interest Coverage Ratio | 4.049 | 0.033 | 1.744 | -1.258 | -3.338 | |
| Short Term Operating Cash Flow Coverage Ratio | 10.726 | 6.980 | 139.952 | -36.709 | 3.908 | |
| Operating Cash Flow Coverage Ratio | 0.570 | 0.103 | 0.416 | -0.109 | 0.012 | |
| Capital Expenditure Coverage Ratio | 5.397 | 3.776 | 6.426 | -1.896 | 0.141 | |
| Dividend Paid And Capex Coverage Ratio | 5.221 | 3.446 | 5.908 | -1.726 | 0.139 | |
| Dividend Payout Ratio | 0.015 | -0.088 | 0.087 | -0.034 | -0.004 | |
| Enterprise Value Multiple | 7.828 | 24.511 | 9.916 | 35.640 | 246.307 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 51.0% | ▼-8.3% | ▼-5.5% |
| Ebit Margin | 13.1% | ▲13.9% | ▲15.0% |
| Ebitda Margin | 23.5% | ▲13.2% | ▲10.5% |
| Operating Profit Margin | 9.2% | ▲9.1% | ▲11.3% |
| Pretax Profit Margin | 10.8% | ▲14.5% | ▲17.7% |
| Continuous Operations Profit Margin | 8.9% | ▲11.9% | ▲13.9% |
| Net Profit Margin | 8.9% | ▲11.9% | ▲13.9% |
| Bottom Line Profit Margin | 8.0% | ▲11.3% | ▲13.4% |
| Current Ratio | 2.708 | ▼-0.017 | ▼-0.521 |
| Quick Ratio | 2.193 | ▲0.175 | ▼-0.240 |
| Solvency Ratio | 0.189 | ▲0.131 | ▲0.096 |
| Cash Ratio | 1.027 | ▲0.279 | ▲0.042 |
| Price To Earnings Ratio | 22.554 | ▲75.708 | ▲22.414 |
| Price To Earnings Growth Ratio | -0.052 | ▼-0.305 | ▼-0.226 |
| Forward Price To Earnings Growth Ratio | -0.052 | ▼-0.305 | ▼-0.226 |
| Price To Earnings Diluted Ratio | 23.777 | ▲76.931 | ▲23.269 |
| Price To Earnings Diluted Growth Ratio | -0.057 | ▼-0.309 | ▼-0.229 |
| Price To Book Ratio | 2.928 | ▲0.435 | ▲0.700 |
| Price To Sales Ratio | 1.792 | ▲0.054 | ▼-0.272 |
| Price To Free Cash Flow Ratio | 10.490 | ▼-12.200 | ▲10.337 |
| Price To Operating Cash Flow Ratio | 8.546 | ▼-8.135 | ▼-28.919 |
| Debt To Assets Ratio | 0.226 | ▼-0.260 | ▼-0.130 |
| Debt To Equity Ratio | 0.601 | ▼-0.855 | ▼-0.265 |
| Debt To Capital Ratio | 0.376 | ▼-0.217 | ▼-0.076 |
| Long Term Debt To Capital Ratio | 0.363 | ▼-0.227 | ▼-0.085 |
| Financial Leverage Ratio | 2.664 | ▼-0.332 | ▲0.257 |
| Working Capital Turnover Ratio | 2.184 | ▲0.449 | ▲0.556 |
| Operating Cash Flow Ratio | 0.666 | ▲0.336 | ▲0.358 |
| Operating Cash Flow Sales Ratio | 0.210 | ▲0.105 | ▲0.115 |
| Free Cash Flow Operating Cash Flow Ratio | 0.815 | ▲0.080 | ▲1.254 |
| Debt Service Coverage Ratio | 5.085 | ▲2.590 | ▲2.275 |
| Interest Coverage Ratio | 4.049 | ▲4.016 | ▲3.803 |
| Short Term Operating Cash Flow Coverage Ratio | 10.726 | ▲3.747 | ▼-14.245 |
| Operating Cash Flow Coverage Ratio | 0.570 | ▲0.467 | ▲0.371 |
| Capital Expenditure Coverage Ratio | 5.397 | ▲1.621 | ▲2.628 |
| Dividend Paid And Capex Coverage Ratio | 5.221 | ▲1.775 | ▲2.623 |
| Dividend Payout Ratio | 0.015 | ▲0.102 | ▲0.020 |
| Enterprise Value Multiple | 7.829 | ▼-16.682 | ▼-57.012 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.58B | $1.07B | $992.6M | $654.1M | $580.4M | |
| Enterprise value | $1.62B | $1.55B | $1.06B | $892.4M | $767.5M | |
| EV / Sales | 1.84x | 2.52x | 2.17x | 2.82x | 3.55x | |
| EV / Op. cash flow | 8.76x | 24.17x | 8.89x | -28.60x | 231.03x | |
| EV / Free cash flow | 10.75x | 32.87x | 10.52x | -18.73x | -37.78x | |
| EV / EBITDA | 7.83x | 24.51x | 9.92x | 35.64x | 246.31x | |
| Net debt / EBITDA | 0.19x | 7.59x | 0.60x | 9.52x | 60.03x | |
| Current ratio | 2.71x | 2.73x | 3.57x | 3.46x | 3.68x | |
| Income quality | 2.36x | -3.46x | 6.33x | 0.65x | -0.08x | |
| Graham number | $49 | — | $24 | — | — | |
| Graham net-net | -$17 | -$24 | -$3 | -$12 | -$14 | |
| Tax burden | 81.8% | 83.4% | 94.5% | 76.4% | 76.0% | |
| Interest burden | 82.7% | 481.8% | 42.5% | 181.0% | 127.0% | |
| Working capital | $475.0M | $334.0M | $374.3M | $244.8M | $234.2M | |
| Invested capital | $1.08B | $992.7M | $656.2M | $567.9M | $608.9M | |
| Return on assets | 5.4% | -1.4% | 2.1% | -6.3% | -5.5% | |
| Operating ROA | 6.0% | 0.1% | 5.6% | -4.6% | -6.5% | |
| Return on tangible assets | 8.7% | -2.7% | 2.8% | -10.0% | -9.5% | |
| Return on equity | 14.5% | -4.3% | 4.1% | -14.1% | -11.9% | |
| Return on invested capital | 5.6% | 0.0% | 5.8% | -4.1% | -4.4% | |
| Return on capital employed | 7.0% | 0.1% | 6.2% | -5.3% | -5.8% | |
| Earnings yield | 4.9% | -1.7% | 1.9% | -7.3% | -7.3% | |
| Free cash flow yield | 9.5% | 4.4% | 10.1% | -7.3% | -3.5% | |
| Capex / Op. cash flow | 18.5% | 26.5% | 15.6% | -52.7% | 711.6% | |
| Capex / Depreciation | 37.5% | 25.0% | 31.0% | 27.6% | 50.0% | |
| Capex / Sales | 3.9% | 2.8% | 3.8% | 5.2% | 10.9% | |
| SG&A / Sales | 36.0% | 40.6% | 33.2% | 39.2% | 39.0% | |
| R&D / Sales | 5.8% | 7.3% | 7.0% | 7.1% | 5.3% | |
| Stock comp / Sales | 4.3% | 4.8% | 4.2% | 4.6% | 4.9% | |
| Intangibles / Total assets | 37.6% | 46.9% | 26.2% | 36.8% | 41.7% | |
| Days sales outstanding | 116d | 132d | 122d | 191d | 217d | |
| Days payables outstanding | 53d | 67d | 74d | 77d | 83d | |
| Operating cycle | 237d | 331d | 345d | 468d | 513d | |
| Cash conversion cycle | 184d | 265d | 271d | 391d | 430d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years